%20(1)_edited.jpg)
%201%20(1).png)
Your content has been submitted
Your content has been submitted
Your content has been submitted
An error occurred. Try again later
Your content has been submitted
An error occurred. Try again later
Your content has been submitted
An error occurred. Try again later
An error occurred. Try again later
An error occurred. Try again later
Your content has been submitted
Your content has been submitted
Your content has been submitted
Your content has been submitted
Your content has been submitted
Your content has been submitted
Your content has been submitted
Your content has been submitted
An error occurred. Try again later
An error occurred. Try again later
Your content has been submitted
Your content has been submitted
Your content has been submitted
50
Countries
have approved the medical use of cannabinoid-based products for symptomatic relief of various medical conditions, including 38 states in the U.S.
+$13
Billion
in revenue for global medical cannabis in 2023.
Current cannabinoid-based products have limited oral absorption, reducing their effectiveness and broader use.
.png)
Elixie has developed a high-absorption drug-delivery technology called NANOLIX, which has been clinically proven to promote the fast, efficient and consistent absorption of cannabinoids and maximize efficacy.
Instant Relief
Quicker onset of action : 4x faster
Bioavailability
Higher rate of efficacy
at a small dose
Consistent Absorption
Predictable and repetitive effect relief for spasticity sufferers
Self Nano Emulsifying Drug Delivery System (SNEDDS) for Oral Drugs
NANOLIX encapsulates cannabinoids in nanoemulsions and is used as a platform to enhance and expand existing API’s, creating cannabinoid 'super drugs' for rapid relief.
NANOLIX Patented
Technology
EU - Granted
US | Canada | Pending
01
.png)
NANOLIX pre-concentrated composition of cannabinoids and Pro-Nano liposphere formulation.
02
.png)
In contact with water, NANOLIX spheres spontaneously formed around the cannabinoids.
03
.png)
The cannabinoids are encapsulated in NANOLIX nanoparticles.
Clinically validated and published in 6 peer reviewed publications
Key International Research and Clinical Collaborators
.png)
Elixie Products
%206%20(1).png)
Elixie's Advanced medicinal cannabis products enable instant relief via convenient oral administration.
We enhance the therapeutic potential of cannabinoids with our patented, clinically validated Nanolix Technology to ensure rapid, effective, and consistent oral absorption.
To allow patients of any age and medical condition to access it, we utilized NANOLIX to develop two product forms for oral administration: a solution and a capsule.
————— NANOLIX® solution
—————NANOLIX® Capsule
%205%20(1).png)
Solution
Liquid NANOLIX
NANOLIX oral solution is a liquid pre-concentrated formulation that combines cannabinoids with Pro-Nano Liposphere (PNL) technology to enhance absorption and provide rapid relief.
Patients or caregivers can use a dosing syringe to measure the precise dose and mix it with water or a soft drink. When the NANOLIX oral solution comes into contact with water, the cannabinoids are instantly nano-encapsulated, forming tiny spheres that promote solubility and stability.
This liquid formulation allows for micro-dosing and a flexible titration regimen, making it ideal for sensitive patient populations.
Capsule
Solid NANOLIX
NANOLIX powder is the solid form of cannabinoids with a Pro-Nano Liposphere (PNL) technology combination, allowing fast-acting capsules or tablets.
The unique feature of NANOLIX is that the cannabinoids are instantly nano-encapsulated when the formulation comes into contact with the aqueous environment of the gastrointestinal (GI) tract, leveraging its self-nano-encapsulating properties.
The solid form of capsules and tablets makes consumption easy, allows precise dosing, and masks the taste of cannabinoids. Patients can use their medicinal cannabis just like any other medication.
Product Development Pipeline
%206.png)
Product Form
Formulation development
Analytical methods development
Pivotal scale-up
Validation & stability
Product launch
Solution
Elinol is eligible for FDA orphan disease designation.
Capsule
Elinol is eligible for FDA orphan disease designation.
%207%20(2).png)
%202%20(1).png)
Elixie was founded in 2019 with its headquarters located in Tel Aviv, Israel. Our deep commitment lies in addressing the pressing healthcare challenges faced by millions of individuals living with chronic conditions.
Elixie is powered by a dedicated team of passionate visionaries who bring together diverse expertise and unwavering commitment. We share a common belief in the transformative power of science, and our relentless pursuit of excellence propels us to explore uncharted territories in nanotechnology, pushing the boundaries to provide innovative solutions for relief.
%20(5).png)
Join us in driving nano-tech healthcare innovation
forward
%201%20(1).png)
Headquarters
No. 4 Ariel Sharon St., Givatayim, Israel
R&D lab:
Tarshish Industrial Park St 5, Caesarea, Israel
Created by Zenverse Studio
Your content has been submitted
2023 Elixie. All right reserved.